Spectrum Pharmaceuticals, Inc.

Symbol: SPPI

NASDAQ

1.03

USD

Market price today

  • -5.7473

    P/E Ratio

  • 0.5829

    PEG Ratio

  • 211.40M

    MRK Cap

  • 0.00%

    DIV Yield

Spectrum Pharmaceuticals, Inc. (SPPI) Stock Price & Analysis

Shares Outstanding

0M

Gross Profit Margin

0.89%

Operating Profit Margin

-1.48%

Net Profit Margin

-1.40%

Return on Assets

-0.33%

Return on Equity

-1.19%

Return on Capital Employed

-0.55%

Company general description and statistics

Sector: Healthcare
Industry: Biotechnology
CEO:Mr. Thomas J. Riga
Full-time employees:86
City:Boston
Address:Pilot House – Lewis Wharf
IPO:1996-09-26
CIK:0000831547

Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology and hematology drug products. The company's products under development include Eflapegrastim, a novel long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia; Poziotinib, a novel irreversible tyrosine kinase inhibitor for non-small cell lung cancer tumors with various mutations; and Anti-CD20-IFNa, an antibody-interferon fusion molecule directed against CD20 that is in Phase I development for the treatment of patients with relapsed or refractory non-Hodgkin's lymphoma, including diffuse large B-cell lymphoma. It has co-development, commercialization, and in-license agreements with Hanmi Pharmaceutical Co. Ltd.; a patent and technology license agreement with The University of Texas M.D. Anderson Cancer Center; and in-license agreement with ImmunGene, Inc. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was incorporated in 1987 and is based in Boston, Massachusetts.

General Outlook

When we look at how much money they make before expenses, they keep 0.889% as profit. This shows they're good at controlling costs and are financially stable. Their operating profit, which is money made from regular business activities, is -1.481%. This means they run their business efficiently. Lastly, after paying all their bills, they still have a profit of -1.400%. This tells us they're good at keeping money after all costs.

Return on Investments

The company's asset efficiency, represented by a robust -0.334% return, is a testament to Spectrum Pharmaceuticals, Inc.'s adeptness in optimizing resource deployment. Spectrum Pharmaceuticals, Inc.'s utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of -1.193%. Furthermore, the proficiency of Spectrum Pharmaceuticals, Inc. in capital utilization is underscored by a remarkable -0.554% return on capital employed.

Stock Prices

Spectrum Pharmaceuticals, Inc.'s stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $1.12, while its low point bottomed out at $1.07. This variance in figures offers investors a lucid insight into the roller-coaster ride that is Spectrum Pharmaceuticals, Inc.'s stock market.

Liquidity Ratios

Analyzing SPPI liquidity ratios reveals its financial health of the firm. The current ratio of 271.03% gauges short-term asset coverage for liabilities. The quick ratio (230.89%) assesses immediate liquidity, while the cash ratio (134.70%) indicates cash reserves.

cards.indicatorcards.value
Current Ratio271.03%
Quick Ratio230.89%
Cash Ratio134.70%

Profitability Ratios

SPPI profitability indicators offer a lens into its earnings landscape. A pretax profit margin of -150.21% underscores its earnings before tax deductions. The effective tax rate stands at 6.82%, revealing its tax efficiency. The net income per EBT, 93.18%, and the EBT per EBIT, 101.40%, provide insights into its earnings hierarchy. Lastly, with an EBIT per revenue ratio of -148.13%, we grasp its operational profitability.

cards.indicatorcards.value
Pretax Profit Margin-150.21%
Effective Tax Rate6.82%
Net Income per EBT93.18%
EBT per EBIT101.40%
EBIT per Revenue-148.13%

Operational Efficiency

Operational metrics shed light on its business agility. With an operating cycle of 2.71, it details the span from stock purchase to revenue. The 2 days it takes to settle debts showcases its creditor relations. Meanwhile, a 1 cash conversion cycle and 76.49% receivables turnover rate reflect its cash flow efficiency and credit management, respectively.

cards.indicatorcards.value
Days of Sales Outstanding231
Days of Inventory Outstanding1643
Operating Cycle2119.83
Days of Payables Outstanding4518
Cash Conversion Cycle-2398
Receivables Turnover0.76
Payables Turnover0.08
Inventory Turnover0.22
Fixed Asset Turnover12.54
Asset Turnover0.24

Cash Flow Ratios

Peering into the cash flow metrics reveals liquidity and operational efficiency. The operating cash flow per share, -0.32, and free cash flow per share, -0.32, depict cash generation on a per-share basis. The cash per share value, 0.28, showcases liquidity position. Lastly, the operating cash flow sales ratio, -2.51, offers insight into cash flow relative to sales.

cards.indicatorcards.value
Operating Cash Flow per Share-0.32
Free Cash Flow per Share-0.32
Cash per Share0.28
Operating Cash Flow Sales Ratio-2.51
Free Cash Flow to Operating Cash Flow Ratio1.01
Cash Flow Coverage Ratio-2.18
Short Term Coverage Ratio-83.90
Capital Expenditure Coverage Ratio-192.52
Dividend Paid and Capex Coverage Ratio-192.52

Debt and Leverage Ratios

Diving into debt and leverage metrics unveils the company's financial structure. The debt ratio, at 27.50%, highlights its total liabilities relative to assets. With a debt-equity ratio of 1.10, we discern the balance between debt and equity financing. The long-term debt to capitalization, 51.83%, and total debt to capitalization, 52.49%, ratios shed light on its capital structure. An interest coverage of -19.33 indicates its ability to manage interest expenses.

cards.indicatorcards.value
Debt Ratio27.50%
Debt Equity Ratio1.10
Long Term Debt to Capitalization51.83%
Total Debt to Capitalization52.49%
Interest Coverage-19.33
Cash Flow to Debt Ratio-2.18
Company Equity Multiplier4.02

Per Share Data

Speaking about the per share data offers a perceptive view of financial distribution. The revenue per share, 0.06, provides a glimpse into top-line earnings distributed across each share. Net income per share, -0.43, reflects the portion of profit attributed to each share. The book value per share, 0.15, represents the net asset value distributed per share, while the tangible book value per share, 0.15, excludes intangible assets.

cards.indicatorcards.value
Revenue Per Share0.06
Net Income Per Share-0.43
Book Value Per Share0.15
Tangible Book Value Per Share0.15
Shareholders Equity Per Share0.15
Interest Debt Per Share0.17

Growth Ratios

EBIT growth, 50.78%, and operating income growth, 50.78%, offer insights into operational profitability progression. The net income growth, 50.70%, showcases bottom-line expansion, and the EPS growth, 57.84%, measures the growth in earnings per share.

cards.indicatorcards.value
EBIT Growth50.78%
Operating Income Growth50.78%
Net Income Growth50.70%
EPS Growth57.84%
EPS Diluted Growth57.84%
Weighted Average Shares Growth18.32%
Weighted Average Shares Diluted Growth18.32%
Operating Cash Flow Growth18.83%
Free Cash Flow Growth18.75%
10-Year Revenue Growth per Share-98.79%
5-Year Revenue Growth per Share-96.34%
10-Year Operating CF Growth per Share-143.10%
5-Year Operating CF Growth per Share-15.95%
3-Year Operating CF Growth per Share56.52%
10-Year Net Income Growth per Share-126.41%
5-Year Net Income Growth per Share60.24%
3-Year Net Income Growth per Share65.18%
10-Year Shareholders Equity Growth per Share-96.87%
5-Year Shareholders Equity Growth per Share-96.31%
3-Year Shareholders Equity Growth per Share-91.16%
10-Year Dividend per Share Growth per Share-100.00%
Receivables Growth1224.22%
Asset Growth-7.36%
Book Value per Share Growth-50.44%
Debt Growth2195.40%
R&D Expense Growth-51.66%

Other Metrics

Venturing into other key metrics unveils diverse facets of financial performance. The enterprise value, 56,581,908.2, captures the company's total value, considering both debt and equity. Income quality, 1.29, assesses the reliability of reported earnings.

cards.indicatorcards.value
Enterprise Value56,581,908.2
Income Quality1.29
Research and Development to Revenue417.27%
Capex to Operating Cash Flow0.28%
Capex to Revenue-2.70%
Capex to Depreciation-110.08%
Stock-Based Compensation to Revenue83.94%
Graham Number1.21
Return on Tangible Assets-75.58%
Graham Net Net0.08
Working Capital58,326,000
Tangible Asset Value27,888,000
Net Current Asset Value25,561,000
Invested Capital1
Average Receivables7,320,500
Average Payables39,681,500
Average Inventory4,615,000
Days Sales Outstanding491
Days Payables Outstanding7761
Days of Inventory On Hand1880
ROIC-125.25%
ROE-2.80%

Valuation Ratios

Exploring the valuation ratios offers insights into perceived market value. The price to book value ratio, 7.72, and the price to book ratio, 7.72, reflect the market's valuation relative to the company's book value. The price to sales ratio, 8.18, provides a perspective on valuation in relation to sales. Ratios like price to free cash flows, -3.24, and price to operating cash flows, -3.20, gauge market valuation against cash flow metrics.

cards.indicatorcards.value
Price Book Value Ratio7.72
Price to Book Ratio7.72
Price to Sales Ratio8.18
Price Cash Flow Ratio-3.20
Price Earnings to Growth Ratio0.58
Enterprise Value Multiple-6.41
Price Fair Value7.72
Price to Operating Cash Flow Ratio-3.20
Price to Free Cash Flows Ratio-3.24
Price to Tangible Book Ratio2.42
Enterprise Value to Sales5.59
Enterprise Value Over EBITDA-0.73
EV to Operating Cash Flow-0.58
Earnings Yield-115.67%
Free Cash Flow Yield-144.04%
security
Trusted project
“All information displayed on the site is verified. High quality project and financial performance”
Eugene Alexeev
NumFin Founder and investing enthusiast

Frequently Asked Question

How many company shares are outstanding in 2024?

There are stock number shares outstanding of Spectrum Pharmaceuticals, Inc. (SPPI) on the NASDAQ in 2024.

What is P/E ratio of enterprise in 2024?

The current P/E ratio of enterprise is -5.747 in 2024.

What is the ticker symbol of Spectrum Pharmaceuticals, Inc. stock?

The ticker symbol of Spectrum Pharmaceuticals, Inc. stock is SPPI.

What is company IPO date?

IPO date of Spectrum Pharmaceuticals, Inc. is 1996-09-26.

What is company current share price?

Current share price is 1.030 USD.

What is stock market cap today?

The market cap of stock today is 211403376.000.

What is PEG ratio in 2024?

The current 0.583 is 0.583 in 2024.

What is the number of employees in 2024?

In 2024 the company has 86.